Arbutus Biopharma (ABUS) Misses Q1 EPS by 8c

Arbutus Biopharma (NASDAQ: ABUS) reported Q1 EPS of ($0.47), $0.08 worse than the analyst estimate of ($0.39). Revenue for the quarter came in at $700 thousand versus the consensus estimate of $220 thousand.

For earnings history and earnings-related data on Arbutus Biopharma (ABUS) click here.

You May Also Be Interested In

• Klarna shares tumble on weak full-year revenue guidance
• Terra Innovatum Global N.V. (NKLR) Misses Q2 EPS by 12c
• Benchmark Reiterates Buy Rating on H World Group Ltd. (HTHT) Following Q2 Print